Back to search

Peptide record

TPDB41352

P04 Anticancer standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41352
P04
Anticancer
Cancer-related peptides
CancerPPD 2.0 dbACP
standard
No
A 20-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0 and dbACP, with an available 3D structural model.
Sequence
IGEHTPSALAIMENANVLAR
Physicochemical Analysis
C90H151N27O29S1
DCQKFWY
A
2107.41
5.30
2
2
10
-1
4.80
0.235
112.50
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
0
0.00
4
Residue Composition
number
4
A
1
R
2
N
0
D
0
C
2
E
0
Q
1
G
1
H
2
I
2
L
0
K
1
M
0
F
1
P
1
S
1
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 4 R: 1 N: 2 D: 0 C: 0 E: 2 Q: 0 G: 1 H: 1 I: 2 L: 2 K: 0 M: 1 F: 0 P: 1 S: 1 T: 1 W: 0 Y: 0 V: 1
Chemical Descriptors
20
C90H151N27O29S1
2107.41
5.30
-1
4.80
0.235
Free
L
Linear
Free
Anticancer
Aldolase A fragment
Evidence Records 2 records
Evidence 1 Activity

Activity

Relative viability
Relative viability = 0.86 at 50 µg/ml
Anticancer

Target

Bone Cancer
MG-63
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Relative viability
Relative viability = 0.83 at 50 µg/ml
Anticancer

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2023